The Claim
The loss of lean body mass associated with glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors is not significantly modified by sex, age, or baseline disease status.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors cause a similar reduction in lean body mass across different sexes, ages, and initial health conditions.
See the scientific wording
The loss of lean body mass associated with glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors is not significantly modified by sex, age, or baseline disease status, indicating that the effect is consistent across diverse patient populations.
These drugs cause the body to lose calories either by making the stomach feel full and reducing food intake, or by making the kidneys spill sugar into the urine. This creates a shortage of energy, so the body breaks down muscle tissue to get amino acids that can be turned into glucose to keep the blood sugar stable.
What the research says
1 studyThis study found that when people lose weight using these diabetes or obesity drugs, they lose a similar amount of muscle regardless of whether they’re male or female, young or old, or have type 1, type 2 diabetes, or just obesity.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.